CRISPR Therapeutics (CRSP) PT Raised to $170 at Needham & Company
Tweet Send to a Friend
Needham & Company analyst Alan Carr raised the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $170.00 (from $105.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
